Nasdaq · Healthcare

Theravance Biopharma, Inc. (TBPH)

As-reported financials and recent SEC filings for Theravance Biopharma, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$107.5M

Net income

$105.9M

Net margin

98.5%

Diluted EPS

$2.06

ROE

35.7%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$107.5M	$64.4M	$57.4M	$51.3M	$55.3M
Gross profit	—	—	—	—	—
Operating income	$-3.6M	$-46.9M	$-56.0M	$-92.0M	$-257.8M
Net income	$105.9M	$-56.4M	$-55.2M	$872.1M	$-199.4M
Diluted EPS	$2.06	$-1.15	$-1.00	$11.85	$-2.87

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-07-01

DEFA14A2026-06-29

8-K2026-06-29

42026-06-23

8-K2026-06-23

42026-06-17

42026-06-16

42026-06-16

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on TBPH

Search Theravance Biopharma, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.